Skip to main content
Fig. 2 | BMC Pharmacology and Toxicology

Fig. 2

From: Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients

Fig. 2

eGFR and UP/Cr ratios. Patients classified according to the eGFR values specified in the CKD guideline: 14 patients in G1 (≥90 mL/min/1.73 m2) (a), 22 patients in G2 (60–89 mL/min/1.73 m2), and G3 (30–59 mL/min/1.73 m2) (b). Patients classified according to the value of UP/Cr ratios specified in the CKD guideline: 26 patients in A1 (<0.15 g/gCr) (c), 10 patients in A2 (0.15–0.49 g/gCr), and A3 (≥0.50 g/gCr) (mean ± SD) (d)

Back to article page